Hypoxic Ischemic Encephalopathy clinical trials

Explore recruiting hypoxic ischemic encephalopathy clinical trials.

Recruiting hypoxic ischemic encephalopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypoxic Ischemic Encephalopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SHINE trial - Effect of Sildenafil in association to Hypothermia on survival without brain lesions In term Neonates with hypoxic-ischemic Encephalopathy: a randomized, double-blinded, placebo-controlled, multicenter trial

France

Phase II and Phase III (Integrated) EU CTIS Study details

Continous fentanyl infusion in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia: pharmacokinetics study

Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

ACUMEN: Phase I Dose Escalation and Cohort Expansion study to affirm the safety of pharmacological doses of a novel formulation of intravenous melatonin in babies with hypoxic-ischaemic encephalopathy (HIE) to augment therapeutic hypothermia (HT) treatment; to reduce the incidence and severity of disability in babies with moderate-severe HIE.

Ireland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Neonatal hypoxic ischemic encephalopathy : safety and feasibility study of a curative treatment with autologous cord blood stem cells (NEOSTEM)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Effect of ALlopurinol in addition to hypothermia for hypoxicischemic Brain Injury on Neurocognitive Outcome

Germany, Italy, Norway, Spain, Finland, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hypoxic Ischemic Encephalopathy trials by city

Hypoxic Ischemic Encephalopathy in Toronto Hypoxic Ischemic Encephalopathy in Vancouver Hypoxic Ischemic Encephalopathy in Montreal Hypoxic Ischemic Encephalopathy in Calgary Hypoxic Ischemic Encephalopathy in Edmonton Hypoxic Ischemic Encephalopathy in Ottawa Hypoxic Ischemic Encephalopathy in Winnipeg Hypoxic Ischemic Encephalopathy in Quebec City Hypoxic Ischemic Encephalopathy in Hamilton Hypoxic Ischemic Encephalopathy in Kitchener Hypoxic Ischemic Encephalopathy in London Hypoxic Ischemic Encephalopathy in Halifax Hypoxic Ischemic Encephalopathy in New York Hypoxic Ischemic Encephalopathy in Los Angeles Hypoxic Ischemic Encephalopathy in Chicago Hypoxic Ischemic Encephalopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease